

29 July 2025

India | Equity Research | Results Update

#### **GAIL India**

Oil & Gas

### Muted quarter, prospects continue to be strong

GAIL India (GAIL) reported 29%/34% YoY dip in Q1FY26 adj. EBITDA/PAT (flat/-13% QoQ) driven by weaker performance of gas trading and petchem. Gas trading performance declined by 47%/11% QoQ/YoY with sharply lower margins offsetting a 6mmscmd YoY jump in volume. Transmission volumes were down 8% YoY due to lower offtake by fertiliser segment (unplanned maintenance), refineries (better liquid fuel pricing) and power (early monsoon), but FY26–28E volume CAGR of 5.0% remains likely, with an imminent uptick in tariffs. During the quarter, there was one-off revenue of INR 1.3bn relating to difference in unified tariff. We cut FY26/27/28E EPS by 6.3%/4.2%/5.6% to factor in lower transmission volumes. Reiterate **BUY** with FY26–28E EPS CAGR of 17%, TP of INR 226 (vs. INR 245).

# Transmission, petchem disappoint; FY26 volume guidance cut for second time since FY25 results

Gas transmission volume of 121mmscmd (-8%/flattish YoY/QoQ) was below our/street's estimates due to lower offtake from fertiliser, refinery and petchem segments. Due to weak demand trends and higher competition from alternate fuels, GAIL has cut guidance for FY26E volumes to 127–128mmscmd (from 132-133 earlier). The earlier guidance was lowered from 137-138mmscmd in the post FY25 results briefing. For petchem, volumes of just 177kt (up 9% YoY/down 18% QoQ) were impacted by higher input costs and a shutdown, which we believe will likely normalise over the next few quarters. Profitability remains elusive, with weak realisations sustaining over the near term.

#### Overall prospects remain promising, but some blips emerge

GAIL's prospects remain strong to drive sustained outperformance over the next 2–3 years. Growing domestic gas supplies, LNG liquefaction capacity and the expectation of relatively moderate pricing of the same, along with normalisation of LPG prices, are all positives with tariff revision – upward by 20–25% in H1FY26E – being a strong possibility (*now partly* baked into our estimates). LPG/LHC volumes see some respite by 0.3mmscmd of New Well Gas allocation (50% of deallocated gas) and petchem volumes and margins should see recovery via capacity expansion and lower gas costs, respectively.

## **Financial Summary**

Y/E March (INR mn)	FY25A	FY26E	FY27E	FY28E
Net Revenue	14,19,035	9,32,767	10,23,746	11,09,356
EBITDA	1,54,318	1,40,476	1,69,900	1,86,061
EBITDA %	10.9	15.1	16.6	16.8
Net Profit	1,06,172	96,129	1,18,876	1,31,406
EPS (INR)	16.1	14.6	18.1	20.0
EPS % Chg YoY	7.3	(9.5)	23.7	10.5
P/E (x)	11.3	12.5	10.1	9.2
EV/EBITDA (x)	9.0	9.6	7.6	6.7
RoCE (Pre-tax) (%)	11.3	9.1	11.2	11.7
RoE (%)	13.1	10.9	12.5	12.7

#### **Probal Sen**

probal.sen@icicisecurities.com +91 22 6807 7274

#### Hardik Solanki

solanki.hardik@icicisecurities.com

#### **Market Data**

1,203bn
13,859mn
GAIL IN
GAIL.BO
246 /151
41.0
27.5

Price Performance (%)	3m	6m	12m
Absolute	(3.5)	10.7	(21.1)
Relative to Sensex	(4.8)	4.5	(21.1)

ESG Score	2023	2024	Change
ESG score	73.3	67.3	(6.0)
Environment	64.9	64.7	(0.2)
Social	74.8	73.1	(1.7)
Governance	74.4	65.7	(8.7)

**Note** - Score ranges from 0 - 100 with a higher score indicating higher ESG disclosures.

Source: SES ESG, I-sec research

Earnings Revisions (%)	FY26E	FY27E	FY28E
Revenue	(1.5)	(2.5)	(2.7)
EBITDA	(5.7)	(3.7)	(5.0)
EPS	(6.3)	(4.2)	(5.6)

#### **Previous Reports**

27-06-2025: <u>Company Update</u>

15-05-2025: <u>Q4FY25 results review</u>



#### Reiterate BUY: Attractive valuation

We have factored in Q1FY26's muted performance (along with softer management guidance) and bake in lower transmission/trading volumes with lower margin assumptions for petchem. Resultantly, we revise our FY26/27/28E EPS down by 6.3/4.2/5.6%.

We continue to see multiple drivers of optimism for the stock. Nearly 16–18mmscmd of volume addition over FY26–28E, stronger tariffs and additional delta from petchem (JBF acquisition to add capacity) imply GAIL could see steady earnings growth over FY26–28E. Post muted stock movement in the last 12 months (down 21%), valuations of 10.1x FY27E EPS and 7.6x FY27E EV/EBITDA are attractive, and at our revised TP of INR 226 offers ~23% upside from CMP. Maintain **BUY**.

### Key downside risks

1) Sharply lower gas consumption trends. 2) Higher gas price impact on petchem/LPG segments. 3) Reduction in pricing gap between US LNG and Asian spot LNG prices.

### Key upside risks

1) Higher gas demand. 2) Higher-than-expected moderation in gas costs. 3) Successful upward revision in tariffs by regulator to factor in GAIL's submissions on cost of internal usage of gas.

### Q1FY26 conference call takeaways

#### **Quarterly performance**

- In Q1FY26, GAIL reported a one-off revenue of INR 1.3bn related to some revision in zonal division of tariffs charged earlier as part of the review process of Integrated vs. Unified tariff by the Petroleum and Natural Gas Regulatory Board (PNGRB).
- During the quarter, pipeline utilisation stood at 58%, while integrated pipeline utilization was 67%.
- Polymer production was impacted because of the annual maintenance shutdown taken in Q1FY26.
- The company reported a marketing margin of INR 9.9bn in Q1FY26, and management maintains its guidance of INR 40–45bn for FY26.

#### **Pipeline**

- Durgapur-Kolkata pipeline section was completed on 18 Jul'25. It connects Bengal Gas Company to the national natural gas grid, with a potential volume of 0.4 mmscmd.
- The Mumbai-Nagpur-Jharsuguda Pipeline, Jagdishpur-Haldia-Bokaro-Dhamra Pipeline, Kochi-Koottanad-Mangalore-Bangalore Pipeline, and Srikakulam-Angul Pipeline are expected to come online in FY26. The Gurdaspur-Jammu Pipeline is scheduled to be completed in FY27.

#### **Capex**

• GAIL has received authorisation from the PNGRB to expand the capacity of its Jamnagar-Loni LPG pipeline from 3.25mt tonnes to 6.5mt. The project is expected to be completed in 3 years, with a capex of INR 50bn.



- The company incurred capex of ~INR 31bn in Q1FY26: INR 5.4bn toward pipelines, INR 5.4bn toward petrochemicals, INR 15bn toward equity contributions, and INR 1.5bn toward other operational capex.
- Capex guidance for FY26 stands at INR 120bn, with allocations as: INR 40bn for petrochemicals, INR 2bn for CGD, INR 25bn for other petrochemicals, INR 5bn for exploration and production, INR 20bn for net-zero initiatives and INR 14bn for operational expenditure.
- Regarding the proposed ethane cracker project in Madhya Pradesh, the company has not yet made an investment decision.

#### CGD

- GAIL has six geographical areas (GAs), with a total 212 CNG stations and 0.44 mn domestic PNG connections as on 30 Jun'25 (26,000 connections were added in Q1FY26). Volume during the quarter was 0.46 mmscmd, with an APM gas share of 0.17 mmscmd and 0.29 mmscmd of RLNG.
- The company plans to add 85 CNG stations and 0.15 mn domestic PNG connections over the next 2 years.
- GAIL Gas, a wholly owned subsidiary of GAIL, reported a PBT of INR 1.5 n (up 1% QoQ) and a PAT of INR 1.1bn (up 6% QoQ) in Q1FY26, with volumes of 7.03mmscmd. GAIL Gas, along with its JVs, added ~23,500 domestic PNG connections and 3 CNG stations during the quarter.
- It has a total of 0.11mn domestic PNG connections and 664 CNG stations as of June 30'25. It plans to add 216 CNG stations and 0.26 mn domestic PNG connections over the next 2 years.

#### **Petchem**

- The PDH-PP plant at Usar (500 KTPA) is delayed due to civil construction and is expected to be commissioned in FY27. The 60 KTPA PP plant at PATA and GAIL Mangalore (JBF) Petrochemicals' 1,250 KTPA capacity are expected to be completed in FY26.
- The loss in the petchem segment in Q1FY26 was due to the PATA annual maintenance shutdown, pressure on polymer prices from international oversupply, and a sharp rise in Henry Hub gas prices (Q1FY26 averaged USD 3.5/MMBtu vs USD 1.77/MMBtu in Q1 FY25).
- The company is hedging input prices for the PATA plant and expects the segment to approach breakeven in FY26.

#### <u>Transmission segment</u>

- Management has revised transmission volume guidance downward to 128 mmscmd for FY26 (from 132mmscmd earlier) and to 136mmscmd for FY27 (from 142mmscmd). This decline is due to:
  - o 3mmscmd reduction in refining (switch to alternate fuels),
  - o 1.6mmscmd drop in power (early onset of monsoon),
  - o 1.4mmscmd loss in the fertilizer segment (unscheduled shutdowns and the KFCL plant not being operational).
- FY27 volume guidance of 132mmscmd is supported by: 3.5mmscmd from CGD,1–
   2 mmscmd from power, some incremental volumes from refineries (e.g. Barauni, Haldia, Guwahati). According to management, CGD demand is growing at 12%



- per year (~5mmscmd), and GAIL owns 65–70% of India's gas pipeline network (implying 3.5mmscmd from this will flow to GAIL).
- Q2FY26TD volumes are ~127mmscmd, driven by increased demand from fertilizer and the PATA plant. ~20% of total volumes come from the petchem and refinery segments, which are price-sensitive.
- Regarding tariff revision, the PNGRB has completed the consultation process, and the final order is pending. Once approved, the revised tariff will be applicable from the following month. Periodic review takes place every 3–5 years.

#### **Others**

- Management expects crude prices to remain in the USD 60-70/bbl range for the
  next few years. Alternate fuels such as naphtha and furnace oil are linked to
  refinery complexity and subdued propane prices, which is a concern. Spot LNG
  prices have remained firm post-winter, leading to difficulty competing with
  alternate fuels.
- The PDH-PP plant is expected to generate a project IRR of 13–14%.
- The company has signed an agreement with BPCL for propane sourcing, benchmarked to the Saudi Aramco CP index.


Exhibit 1: Q1FY26 (standalone) result snapshot

INR mn	Q1FY26	Q1FY25	YoY % Chg	Q4FY25	QoQ % Chg
Net Sales	3,46,359	3,36,738	2.9	3,56,852	(2.9)
EBITDA	32,007	45,281	(29.3)	32,164	(0.5)
EBIT	23,179	34,792	(33.4)	23,130	0.2
Rep. PAT	18,863	27,240	(30.8)	20,490	(7.9)
Adj. PAT	17,868	27,240	(34.4)	20,490	(12.8)
Adj. EPS (INR)	2.7	4.1	(34.4)	3.1	(12.8)
Volumes					
NG transmission (mmscmd)	120.6	131.8	(8.5)	120.8	(0.2)
NG sales (mmscmd)	105.5	99.5	6.0	106.5	(1.0)
Petchem sales (kt)	177.0	169.0	4.7	229.0	(22.7)
LPG & liquid hydrocarbons (kt)	198.0	218.0	(9.2)	198.0	-
Segment EBIT					
Natural Gas transmission (Adj)	14,246	14,469	(1.5)	12,684	12.3
LPG transmission	1,203	808	48.9	1,152	4.4
Natural Gas Trading	10,716	20,328	(47.3)	12,037	(11.0)
Petrochemicals	(2,486)	(414)	500.6	(1,580)	
LPG and Liquid Hydrocarbon	2,050	2,299	(10.8)	2,920	(29.8)
Others	1,912	1,675	14.2	1,158	65.2
Total	27,640	39,163	(29.4)	28,370	(2.6)

Source: I-Sec research, Company data




# **Exhibit 2:** Transmission volumes remain muted YoY in Q1FY26 while trading volumes improved...




Source: Company data, I-Sec research

### Exhibit 3: ...blended trading margin declined QoQ/YoY




Source: Company data, I-Sec research

#### Exhibit 4: Petchem margins and volumes declined YoY




Source: Company data, I-Sec research

## Exhibit 5: LPG segment earnings and volumes declined YoY






#### Exhibit 6: Petchem and trading segments remained weak in Q1FY26




Source: Company data, I-Sec research

**Exhibit 7:** Diversified EBITDA mix; gas transmission and trading are the largest contributors




Source: Company data, I-Sec research

Exhibit 8: Transmission and trading volumes to grow steadily over FY26–28E




Source: Company data, I-Sec research

**Exhibit 9: Pipeline network** 




Source: Company data, I-Sec research

**Exhibit 10:** Improvement in blended margins for transmission over FY26–28E






**Exhibit 11:** Gas transmission remains key component of overall capital employed




**Exhibit 12:** Return ratios remain healthy



Source: Company data, I-Sec research

Source: Company data, I-Sec research

Exhibit 13: Gap in US HH, term and spot LNG remains material



Source: Bloomberg, CME futures I-Sec research


**Exhibit 14:** Sensitivity of trading gains to differential with term and spot LNG prices

	vs. Spot LNG	vs. Term LNG	vs. Spot LNG	vs. Term LNG
Price (USD/mmbtu)	3.3	3.9	3.3	3.9
Delivered Price (USD/mmbtu)	8.8	9.5	8.8	9.5
Spot LNG Slope Assumed	16%	13%	16%	13%
Brent (USD/bbl)	68	68	70	70
USD/mmbtu	10.9	9.8	11.2	10.1
Premium/(discount) of Spot to HH Delivered price	2.1	0.4	2.4	0.6
Assumed volumes unhedged (mmt)	1.0	1.0	1.0	1.0
Additional margin potential (INR mn)	9,023	1,536	10,408	2,661

Source: Company data, Bloomberg, I-Sec research




## **Exhibit 15:** Petchem EBITDA to improve gradually over FY26–28E




Source: Company data, I-Sec research

# **Exhibit 16:** LPG production and EBITDA likely to improve over FY26–28E



Source: Company data, I-Sec research

# Exhibit 17: EBITDA and PAT to grow at 15.1%/16.9% CAGR over FY26–28E



Source: Company data, I-Sec research

# **Exhibit 18:** Strong cashflow to suffice for capex requirements






Exhibit 19: Subsidiaries and associates' profits

INR mn	% Share holding	Investment	PAT (FY25)	PAT (FY24)
GAIL			1,13,120	88,360
Subsidiaries		50,960	3,520	4,150
GAIL GAS	100%	20,610	4,550	3,180
GGSPL	100%	530	180	110
GGUI	100%	1,870	-180	-130
Bengal Gas Company Limited	88%	8,040	-90	-110
Konkan LNG Limited	93%	8,860	-1,250	-2,490
TNGCL	49%	150	440	410
GMPL	100%	10,900	10	3,220
Less: Minority Interest	-		-130	-40
Associates		28,440	12,490	14,360
MGL	33%	320	3,380	4,150
PLL	13%	990	5,030	4,560
BCPL	70%	9,920	110	-1,120
IGL	23%	320	3,870	4,470
OPαL	49%	9,950	-1,560	0
China Gas	3%	970	1,030	1,440
Fayum Gas	19%	80	30	30
Ramagundam Fertilizer	14%	2,700	600	660
ONGC Tripura Power Company Ltd	26%	3,190	20	180
oint Ventures ( Vs)		16,820	2,490	2,510
MNGL		2,300	1,470	1,370
CGD JVs & Others (BGL, CUGL, GGL, MNGL, AGL, VGL, TAPI, IGGL)		13,540	14,530	1,020
Adjustments				
Add: Elimination of Dividend			-5,920	-6,810
Add: Elimination Profit/Loss recognized from investments			0	0
Less: Others			-1350	3580
Consolidated			1,24,500	98,990

Source: Company data, I-Sec research

### Exhibit 20: Pipeline and re-gas terminal in India






Exhibit 21: Major petchem and pipeline projects

Major Pipeline (INR bn)	Lengths of Pipelines (Km)/Capacity	Commissioned length (Km)	Expected Completion Date	Approved Cost	Capital Commitment	Actual Capex up to 31.03.2025
Durgapur-Haldia P/L (JHBDPL 3B)	294	132	31st Dec'25	2.4	2.4	2.2
Dhamra-Haldia P/L	253	150	31st Dec'25	1.0	1.0	0.8
KKBMPL – II P/L – Krishnagiri – Coimbatore Section	322	-	31st Dec'25	2.4	1.8	1.3
Srikakulam-Angul P/L	743	421 (completed)	30th Jun'25	2.8	2.5	2.2
Mumbai-Nagpur-Jharsuguda P/L	1,702		30th Jun'25	7.8	7.2	6.2
Gurdaspur - Jammu P/L	152	-	Fy27	0.5	0.3	0.1
C2/C3 Pipeline (Vijaipur to Pata)	360	-	15th Jan'27	1.8	1.0	0.0
Major PC Projects						
Propane Dehydrogenation & Polypropylene Project (PDH-PP), Usar	500 KTPA	NA	Fy27	11.3	10.3	6.5
IPA, USAR	50 KTPA	NA	August'27	0.5	0.0	0.0
Polypropylene Project (PP), PATA	60 KTPA	NA	June'25	1.3	1.2	1.0
GMPL – PTA Plant	1,250 KTPA	NA	February'26	4.2	3.7	2.6


Source: I-Sec research, Company data

Exhibit 22: Valuation summary – material upside from CMP seen over next 12–18 months

Business		INR-bn	INR/share	Break-up
Gas and LPG transmission	DCF	778	118	49%
Gas trading	EV/EBITDA (6x FY28E)	367	56	23%
Petrochemicals	EV/EBITDA (6.5x FY28E)	17	3	1%
LPG and other hydrocarbon production	EV/EBITDA (6x FY28E)	63	10	4%
CGD entities other than IGL/MGL	15x FY28E EPS	100	15	6%
Investments	Market value	255	39	16%
		1,580	240	100%
Less: net debt		94	14	
Sum of parts valuation		1,380	226	
CMP			183	
Upside (downside) %			23%	


Source: Company data, I-Sec research

Exhibit 23: P/E valuation trading near upper band



Source: Company data, I-Sec research

Exhibit 24: P/B valuation trading near upper band






## **Exhibit 25: Shareholding pattern**

%	Dec'24	Mar'25	Jun'25
Promoters	51.9	51.9	51.9
Institutional investors	32.6	32.8	32.8
MFs and other	10.1	11.4	11.0
FIs/ Banks	0.0	0.0	0.0
Insurance Cos.	6.5	6.6	6.8
FIIs	16.1	14.8	14.9
Others	15.5	15.3	15.3

Source: Bloomberg, I-Sec research

#### Exhibit 26: Price chart



Source: Bloomberg, I-Sec research



## **Financial Summary**

#### **Exhibit 27: Profit & Loss**

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Net Sales	14,19,035	9,32,767	10,23,746	11,09,356
EBITDA	1,54,318	1,40,476	1,69,900	1,86,061
EBITDA Margin (%)	10.9	15.1	16.6	16.8
Depreciation & Amortization	37,992	42,356	45,956	49,556
EBIT	1,16,326	98,120	1,23,944	1,36,505
Interest expenditure	7,480	6,599	3,840	1,995
Other Non-operating Income	12,676	10,034	10,811	12,384
PBT	1,45,923	1,01,555	1,30,915	1,46,894
Profit / (Loss) from Associates	14,902	20,135	20,912	21,485
Less: Taxes	36,326	25,561	32,951	36,973
PAT	1,09,596	75,994	97,964	1,09,921
Less: Minority Interest	-	-	-	-
Net Income (Reported)	1,24,498	96,129	1,18,876	1,31,406
Extraordinaries (Net)	24,400	-	-	-
Recurring Net Income	1,06,172	96,129	1,18,876	1,31,406

Source Company data, I-Sec research

#### **Exhibit 28: Balance sheet**

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Total Current Assets	2,15,017	1,80,415	2,14,128	2,58,174
of which cash & bank	27,205	26,671	45,944	75,998
Total Current Liabilities & Provisions	2,20,531	2,21,083	2,44,414	2,61,949
Net Current Assets	(5,514)	(40,668)	(30,286)	(3,774)
Other Non Current Assets	-	-	-	-
Net Fixed Assets	5,88,355	6,35,999	6,80,043	7,20,486
Other Fixed Assets	-	-	-	-
Capital Work in Progress	2,74,211	2,74,211	2,74,211	2,74,211
Non Investment	2,53,905	2,53,905	2,53,905	2,53,905
Current Investment	-	-	-	-
Deferred Tax Assets	-	-	-	-
Total Assets	11,10,957	11,23,446	11,77,872	12,44,827
Liabilities				
Borrowings	2,15,954	1,65,190	1,40,190	1,15,190
Deferred Tax Liability	42,598	42,598	42,598	42,598
Lease Liability	-	-	-	-
Other Liabilities	-	-	-	-
Equity Share Capital	65,751	65,751	65,751	65,751
Reserves & Surplus*	7,84,225	8,47,478	9,26,903	10,18,859
Total Net Worth	8,49,976	9,13,229	9,92,654	10,84,610
Minority Interest	2,429	2,429	2,429	2,429
Total Liabilities	11,10,957	11,23,446	11,77,872	12,44,827

Source Company data, I-Sec research

#### **Exhibit 29: Quarterly trend**

(INR mn, year ending March)

	Sep-24	Dec-24	Mar-25	Jun-25
Net Sales	3,29,117	3,49,371	3,56,852	3,46,359
% growth (YOY)	-2.3%	6.2%	2.1%	-2.9%
EBITDA	37,450	28,378	32,164	32,007
Margin %	11.4%	8.1%	9.0%	9.2%
Other Income	7,135	7,497	5,664	2,919
Extraordinaries		24,400		1,330
Adjusted Net Profit	26,719	20,415	20,490	17,868

Source Company data, I-Sec research

#### **Exhibit 30: Cashflow statement**

(INR mn, year ending March)

	FY25A	FY26E	FY27E	FY28E
Cash Flow from				
operation before working	1,81,467	1,40,476	1,69,900	1,86,061
Capital				
Working Capital Changes	787	34,620	8,891	3,542
Tax	(24,903)	(25,561)	(32,951)	(36,973)
Operating Cashflow	1,57,350	1,49,535	1,45,840	1,52,630
Capital Commitments	(79,297)	(90,000)	(90,000)	(90,000)
Free Cashflow	78,053	59,535	55,840	62,630
Others CFI	21,439	30,169	31,724	33,869
Cashflow from Investing	(57,858)	(59,831)	(58,276)	(56,131)
Activities	(37,030)	(55,051)	(30,270)	(50,151)
Inc (Dec) in Borrowings	(32,124)	(50,764)	(25,000)	(25,000)
Interest Cost	(14,858)	(6,599)	(3,840)	(1,995)
Others	(42,426)	(32,876)	(39,451)	(39,451)
Cash flow from	(89,409)	(90,238)	(68,291)	(66,446)
Financing Activities	(33, 33,	(,,	(,,	(,
Chg. in Cash & Bank balance	10,084	(534)	19,273	30,054
Closing cash & balance	27,205	26,671	45,944	75,998

Source Company data, I-Sec research

### **Exhibit 31:** Key ratios

(Year ending March)

	FY25A	FY26E	FY27E	FY28E
Per Share Data (INR)				
Recurring EPS	16.1	14.6	18.1	20.0
Diluted EPS	16.1	14.6	18.1	20.0
Recurring Cash EPS	21.9	21.1	25.1	27.5
Dividend per share (DPS)	7.5	5.0	6.0	6.0
Book Value per share (BV)	129.3	138.9	151.0	165.0
Dividend Payout (%)	46.4	34.2	33.2	30.0
Growth (%)				
Net Sales	6.5	(34.3)	9.8	8.4
EBITDA	7.9	(9.0)	20.9	9.5
EPS	7.3	(9.5)	23.7	10.5
Valuation Ratios (x)				
P/E	11.3	12.5	10.1	9.2
P/CEPS	8.3	8.7	7.3	6.6
P/BV	1.4	1.3	1.2	1.1
EV / EBITDA	9.0	9.6	7.6	6.7
EV / Operating Income	10.8	12.4	9.6	8.3
Dividend Yield (%)	4.1	2.7	3.3	3.3
Operating Ratios				
EBITDA Margins (%)	10.9	15.1	16.6	16.8
Effective Tax Rate (%)	24.9	25.2	25.2	25.2
Net Profit Margins (%)	7.5	10.3	11.6	11.8
NWC / Total Assets (%)	(0.5)	(3.6)	(2.6)	(0.3)
Fixed Asset Turnover (x)	1.8	1.1	1.1	1.1
Working Capital Days	20.5	18.1	23.9	23.6
Net Debt / Equity %	22.2	15.2	9.5	3.6
Profitability Ratios				
RoCE (%)	8.5	6.8	8.4	8.7
RoCE (Pre-tax) (%)	11.3	9.1	11.2	11.7
RoE (%)	13.1	10.9	12.5	12.7



This report may be distributed in Singapore by ICICI Securities, Inc. (Singapore branch). Any recipients of this report in Singapore should contact ICICI Securities, Inc. (Singapore branch) in respect of any matters arising from, or in connection with, this report. The contact details of ICICI Securities, Inc. (Singapore branch) are as follows: Address: 10 Collyer Quay, #40-92 Ocean Financial Tower, Singapore - 049315, Tel: +65 6232 2451 and email: navneet\_babbar@icicisecuritiesinc.com, Rishi\_agrawal@icicisecuritiesinc.com and Kadambari\_balachandran@icicisecuritiesinc.com.

"In case of eligible investors based in Japan, charges for brokerage services on execution of transactions do not in substance constitute charge for research reports and no charges are levied for providing research reports to such investors."

New I-Sec investment ratings (all ratings based on absolute return; All ratings and target price refers to 12-month performance horizon, unless mentioned otherwise) BUY: >15% return; ADD: 5% to 15% return; HOLD: Negative 5% to Positive 5% return; REDUCE: Negative 5% to Negative 15% return; SELL: < negative 15% return

#### ANALYST CERTIFICATION

I/We, Probal Sen, CA, MBA; Hardik Solanki, CA; authors and the names subscribed to this report, hereby certify that all of the views expressed in this research report accurately reflect our views about the subject issuer(s) or securities. We also certify that no part of our compensation was, is, or will be directly or indirectly related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of the ICICI Securities Inc. It is also confirmed that above mentioned Analysts of this report have not received any compensation from the companies mentioned in the report in the preceding twelve months and do not serve as an officer, director or employee of the companies mentioned in the report.

#### Terms & conditions and other disclosures:

ICICI Securities Limited (ICICI Securities) is a full-service, integrated investment banking and is, inter alia, engaged in the business of stock brokering and distribution of financial products. Registered Office Address: ICICI Venture House, Appasaheb Marathe Marg, Prabhadevi, Mumbai - 400 025. CIN: L67120MH1995PLC086241, Tel: (91 22) 6807 7100. ICICI Securities is Sebi registered stock broker, merchant banker, investment adviser, portfolio manager, Research Analyst and Alternative Investment Fund. ICICI Securities is registered with Insurance Regulatory Development Authority of India Limited (IRDAI) as a composite corporate agent and with PFRDA as a Point of Presence. ICICI Securities Limited Research Analyst SEBI Registration Number – INH000000990. ICICI Securities Limited SEBI Registration is INZ000183631 for stock broker. ICICI Securities AIF Trust's SEBI Registration number is IN/AIF3/23-24/1292 ICICI Securities is a subsidiary of ICICI Bank which is India's largest private sector bank and has its various subsidieries engaged in businesses of housing finance, asset management, life insurance, general insurance, venture capital fund management, etc. ("associates"), the details in respect of which are available on <a href="https://www.icicibank.com">www.icicibank.com</a>.

ICICI Securities is one of the leading merchant bankers/ underwriters of securities and participate in virtually all securities trading markets in India. We and our associates might have investment banking and other business relationship with a significant percentage of companies covered by our Investment Research Department. ICICI Securities and its analysts, persons reporting to analysts and their relatives are generally prohibited from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover.

Recommendation in reports based on technical and derivative analysis centre on studying charts of a stock's price movement, outstanding positions, trading volume etc as opposed to focusing on a company's fundamentals and, as such, may not match with the recommendation in fundamental reports. Investors may visit icicidirect.com to view the Fundamental and Technical Research Reports.

Our proprietary trading and investment businesses may make investment decisions that are inconsistent with the recommendations expressed herein.

ICICI Securities Limited has two independent equity research groups: Institutional Research and Retail Research. This report has been prepared by the Institutional Research. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the Retail Research.

The information and opinions in this report have been prepared by ICICI Securities and are subject to change without any notice. The report and information contained herein is strictly confidential and meant solely for the selected recipient and may not be altered in any way, transmitted to, copied or distributed, in part or in whole, to any other person or to the media or reproduced in any form, without prior written consent of ICICI Securities. While we would endeavour to update the information herein on a reasonable basis, ICICI Securities is under no obligation to update or keep the information current. Also, there may be regulatory, compliance or other reasons that may prevent ICICI Securities from doing so. Non-rated securities indicate that rating on a particular security has been suspended temporarily and such suspension is in compliance with applicable regulations and/or ICICI Securities policies, in circumstances where ICICI Securities might be acting in an advisory capacity to this company, or in certain other circumstances. This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. ICICI Securities will not treat recipients as customers by virtue of their receiving this report. Nothing in this report constitutes investment, legal, accounting and tax advice or a representation that any investment or strategy is suitable or appropriate to your specific circumstances. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient. This may not be taken in substitution for the exercise of independent judgment by any recipient. The recipient should independently evaluate the investment risks. The value and return on investment may vary because of changes in interest rates, foreign exchange rates or any other reason. ICICI Securities accepts no liabilities whatsoever for any loss or damage of any kind arising out of the use of this report. Past performance is not necessarily a guide to future performance. Investors are advised to see Risk Disclosure Document to understand the risks associated before investing in the securities markets. Actual results may differ materially from those set forth in projections. Forward-looking statements are not predictions and may be subject to change without notice.

ICICI Securities or its associates might have managed or co-managed public offering of securities for the subject company or might have been mandated by the subject company for any other assignment in the past twelve months.

ICICI Securities or its associates might have received any compensation from the companies mentioned in the report during the period preceding twelve months from the date of this report for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory service in a merger or specific transaction.

ICICI Securities or its associates might have received any compensation for products or services other than investment banking or merchant banking or brokerage services from the companies mentioned in the report in the past twelve months.

ICICI Securities encourages independence in research report preparation and strives to minimize conflict in preparation of research report. ICICI Securities or its analysts did not receive any compensation or other benefits from the companies mentioned in the report or third party in connection with preparation of the research report. Accordingly, neither ICICI Securities nor Research Analysts and their relatives have any material conflict of interest at the time of publication of this report.

Compensation of our Research Analysts is not based on any specific merchant banking, investment banking or brokerage service transactions.

ICICI Securities or its subsidiaries collectively or Research Analysts or their relatives do not own 1% or more of the equity securities of the Company mentioned in the report as of the last day of the month preceding the publication of the research report.

Since associates of ICICI Securities and ICICI Securities as a entity are engaged in various financial service businesses, they might have financial interests or actual/beneficial ownership of one percent or more or other material conflict of interest in various companies including the subject company/companies mentioned in this report.

ICICI Securities may have issued other reports that are inconsistent with and reach different conclusion from the information presented in this report. Neither the Research Analysts nor ICICI Securities have been engaged in market making activity for the companies mentioned in the report.

We submit that no material disciplinary action has been taken on ICICI Securities by any Regulatory Authority impacting Equity Research Analysis activities.

This report is not directed or intended for distribution to, or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject ICICI Securities and affiliates to any registration or licensing requirement within such jurisdiction. The securities described herein may or may not be eligible for sale in all jurisdictions or to certain category of investors. Persons in whose possession this document may come are required to inform themselves of and to observe such restriction.

This report has not been prepared by ICICI Securities, Inc. However, ICICI Securities, Inc. has reviewed the report and, in so far as it includes current or historical information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.



#### Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. None of the research recommendations promise or guarantee any assured, minimum or risk free return to the investors.

ICICI Securities Limited has not used any Artificial Intelligence tools for preparation of this Research Report.

SEBI Guidelines for Research Analyst (RA) requires all RAs to disclose terms and conditions pertaining to Research Services to all clients. Please go through the "Mandatory terms and conditions" and "Most Important Terms and Conditions. (Link)

Name of the Compliance officer (Research Analyst): Mr. Atul Agrawal, Contact number: 022-40701000, E-mail Address: complianceofficer@icicisecurities.com

 $For any queries or grievances: \underline{Mr.\ Bhavesh\ Soni} \quad Email\ address: \underline{headservicequality@icicidirect.com} \ Contact\ Number: 18601231122$